KAHF Biotech, Inc. has successfully raised its initial seed round at a $10 million valuation cap, fully compliant with U.S. Securities and Exchange Commission (SEC) regulations.
This funding will support the development of our Innovative therapeutic monoclonal antibody, advancing the identification and optimization of lead mAbs for Investigational New Drug (IND)-enabling studies. This milestone positions KAHF Biotech to reach the IND stage and transition toward clinical development.
Our lead program targets pancreatic ductal adenocarcinoma (PDAC), with follow-on indications in colorectal cancer, ovarian cancer, and other solid tumors. We are specifically aiming to address one of the greatest unmet needs in oncology: cancer metastasis.
In parallel, we are expanding into next-generation modalities, including Antibody-Drug Conjugates (ADCs), Antibody Intracellular Delivery Conjugate (AIDC), and Degrader Antibody Conjugates (DACs), as we continue to push the frontiers of targeted cancer therapeutics.
We are deeply grateful to our early supporters and investors for believing in KAHF Biotech’s mission. Most importantly, we want to acknowledge our incredible team-your dedication, scientific rigor, and relentless commitment to advancing therapies for patients are what make milestones like this possible.
Muhammad Sadeqi Nezhad
Founder & Chief Executive Officer
KAHF Biotech, Inc.